Table 2 Clinical trials with CSF1/CSF1R inhibitors in combination with anti-tumor therapies (excluding cancer-immunotherapy doublets)
From: Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy
Class | Target | Compound | Combination partner | Clinical phase | Sponsor | Indication | ClinicalTrials.gov identifier | Status/Results | Reference |
|---|---|---|---|---|---|---|---|---|---|
Small molecules | CSF1R (and cKIT, Flt3) | Pexidartinib (PLX3397, PLX108-01) | Androgen-deprivation therapy plus external radiotherapy | 1 | Plexxikon/Daiichi Sankyo | Prostate cancer | NCT02472275 | Ongoing | - |
Paclitaxel | 1 | Plexxikon/Daiichi Sankyo | Solid tumors | NCT01525602 | ORR: 4/23 (17%) CBR: 14/23 (61%) | [35] | |||
Eribulin | 1/2 | Plexxikon/Daiichi Sankyo | Breast cancer | NCT01596751 | Ongoing | - | |||
Temozolomide plus external radiotherapy | 1/2 | Plexxikon/Daiichi Sankyo | GBM | NCT01790503 | Not yet reported | - | |||
Vemurafenib | 1 | Plexxikon/Daiichi Sankyo | BRAF-mutated melanoma | NCT01826448 | Terminated | - | |||
PLX9486 (KIT inhibitor) | 1/2 | Plexxikon/Daiichi Sankyo | GIST | NCT02401815 | Ongoing | - | |||
Sirolimus | 1/2 | Plexxikon/Daiichi Sankyo | Advanced sarcomas, MPNST | NCT02584647 | Ongoing, not yet reported | [73] | |||
Monoclonal antibodies | CSF1R | Emactuzumab (RG7155) | Paclitaxel | 1 | Roche | Ovarian and breast cancer | NCT01494688 | Not yet reported | - |
CSF1R | Emactuzumab (RG7155) | Paclitaxel plus bevacizumab | 2 | Roche | Ovarian cancer | NCT02923739 | Ongoing | - | |
CSF1 | MCS110 | Carboplatin plus gemcitabine | 2 | Novartis | TNBC | NCT02435680 | Ongoing | - | |
CSF1 | PD-0360324 | Cyclophosphamide | 2 | Pfizer | Recurrent platinum-resistant epithelial ovarian, peritoneal, or fallopian tube cancer | NCT02948101 | Ongoing | - |